Dorothy Williams, MD
Neurology · Salt Lake City, UTNPI 1619992708
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for neurology clinicians in UT, where the typical reported total is $626.
Across 24 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$77
- Boston Scientific$36
- Bayer$35
- Teva Pharmaceuticals USA, Inc.$35
- Novo Nordisk$26
- Biohaven Pharmaceutical Holding Company Ltd.$19
- plus $138 from 9 others
What the payments were for
- Food & beverage$35597%
- Education$123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 5 | $77 |
| Boston Scientific | 2 | $36 |
| Bayer | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Novo Nordisk | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Amgen | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
How this compares
$367 in reported general payments places this provider in the 45th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 19 | $16,515 |
| Gabapentin | 30 | $603 |
| Oxcarbazepine | 19 | $556 |
| Lamotrigine | 28 | $522 |
| Primidone | 13 | $442 |
| Pregabalin | 24 | $73 |
| Metoclopramide Hcl | 12 | $29 |
Paid to pharmacies, not to this prescriber.
Other neurology in Salt Lake City
- Timothy WestSalt Lake City$856K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Albert SmithSalt Lake City$122K
- John FoleySalt Lake City$99K
- Kevin BrennanSalt Lake City$81K
- Lucy DewittSalt Lake City$81K
- Nicholas JohnsonSalt Lake City$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.